{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:09:04Z","timestamp":1788703744578,"version":"build-2803163510"},"reference-count":353,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.addr.2026.115958","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:56:53Z","timestamp":1788278213000},"page":"115958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From conventional biologics\u2013device combination products to advanced therapies: current state and future trends in patient-centric delivery"],"prefix":"10.1016","volume":"239","author":[{"given":"Akhilesh","family":"Bhambhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Y","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115958_bb0005","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","article-title":"Biopharmaceutical benchmarks 2022","volume":"40","author":"Walsh","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115958_bb0010","doi-asserted-by":"crossref","unstructured":"Ten threats to global health in 2019, 2021.","DOI":"10.1007\/978-3-030-54161-3_294"},{"key":"10.1016\/j.addr.2026.115958_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122312","article-title":"Delivery of biologics: Topical administration","volume":"302","author":"Kulchar","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115958_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051415","article-title":"Challenges and opportunities in the oral delivery of recombinant biologics","volume":"15","author":"Masloh","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115958_bb0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coph.2017.07.003","article-title":"Oral delivery of biologics using drug-device combinations","volume":"36","author":"Caffarel-Salvador","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.addr.2026.115958_bb0030","article-title":"Nanoparticle based oral delivery of vaccines: A promising solution for immunization challenges in developing nations","volume":"681","author":"Tafere","year":"2025","journal-title":"A comprehensive review, International Journal of Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115958_bb0035","unstructured":"FDA Approves Required Labeling Changes for Increased Risk of Hematologic Malignancy Following Treatment with Skysona (elivaldogene autotemcel), 2025."},{"key":"10.1016\/j.addr.2026.115958_bb0040","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2026.115958_bb0045","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/hum.2022.090","article-title":"Regulatory consideration for the nonclinical safety assessment of gene therapies","volume":"33","author":"Moffit","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2026.115958_bb0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-021-01333-6","volume":"27","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0055","first-page":"86","article-title":"Selection of containers\/closures for use in lyophilization applications: Possibilities and limitations","volume":"13","author":"Bhambhani","year":"2010","journal-title":"Am. Pharmaceutical Rev."},{"key":"10.1016\/j.addr.2026.115958_bb0060","unstructured":"U.S. FDA, Container closure systems for packaging human drugs and biologics, Guidance for Industry (1999). Container Closure Systems for Human Drugs and Biological Products. U.S. FDA Draft Guidance (2026)."},{"key":"10.1016\/j.addr.2026.115958_bb0065","first-page":"2025","author":"Advancing Health Through Innovation","year":"2024","journal-title":"New Drug Therapy Approvals"},{"key":"10.1016\/j.addr.2026.115958_bb0070","unstructured":"Biological License Application, Approvals (2025) (www.fda.gov)."},{"key":"10.1016\/j.addr.2026.115958_bb0075","unstructured":"Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review."},{"key":"10.1016\/j.addr.2026.115958_bb0090","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2014.01.076","article-title":"Microneedle patches: usability and acceptability for self-vaccination against influenza","volume":"32","author":"Norman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb0095","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/17425247.2018.1522301","article-title":"Dissolving microneedles for intradermal vaccination: manufacture, formulation, and stakeholder considerations","volume":"15","author":"Rodgers","year":"2018","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"74","key":"10.1016\/j.addr.2026.115958_bb0100","first-page":"21752","article-title":"Guidance for Industry on How To Write a Request for Designation","volume":"76","year":"2011","journal-title":"Federal Register"},{"key":"10.1016\/j.addr.2026.115958_bb0105","unstructured":"Guideline on quality of transdermal patches, in: E.M.A. (EMA) (Ed.), 2014."},{"key":"10.1016\/j.addr.2026.115958_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200220010-00001","article-title":"Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis","volume":"20","author":"Beutels","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.addr.2026.115958_bb0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.vaccine.2012.10.103","article-title":"Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review","volume":"31","author":"Ozawa","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb0120","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.vaccine.2014.01.081","article-title":"Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007\u20132012","volume":"32","author":"Larson","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb0125","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.vaccine.2019.02.079","article-title":"End-user acceptability study of the nanopatch\u2122; a microarray patch (MAP) for child immunization in low and middle-income countries","volume":"37","author":"Guillermet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb0130","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1016\/j.vaccine.2019.06.079","article-title":"Perceptions of influenza and pneumococcal vaccine uptake by older persons in Australia","volume":"37","author":"Briggs","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb0135","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1016\/j.vaccine.2019.03.035","article-title":"Potential use of microarray patches for vaccine delivery in low- and middle- income countries","volume":"37","author":"Peyraud","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb0080","unstructured":"Current Good Manufacturing Practice Requirements for Combination Products, 2017."},{"key":"10.1016\/j.addr.2026.115958_bb0085","author":"Questions & Answers for applicants","year":"2017"},{"key":"10.1016\/j.addr.2026.115958_bb0140","series-title":"Sterile Drug Products Produced by Aseptic Processing \u2014","author":"U.S. FDA","year":"2004"},{"key":"10.1016\/j.addr.2026.115958_bb0145","unstructured":"21CFR 211: CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS."},{"key":"10.1016\/j.addr.2026.115958_bb0150","unstructured":"21 CFR 820 Quality system regulation."},{"key":"10.1016\/j.addr.2026.115958_bb0155","unstructured":"21 CFR 600 BIOLOGICAL PRODUCTS: GENERAL."},{"key":"10.1016\/j.addr.2026.115958_bb0160","first-page":"871","article-title":"Muromonab CD3","volume":"37","author":"Todd","year":"1989","journal-title":"A review of its pharmacology and therapeutic potential, Drugs"},{"key":"10.1016\/j.addr.2026.115958_bb0165","author":"Antibody therapeutics approved or in regulatory review in the EU or US"},{"key":"10.1016\/j.addr.2026.115958_bb0170","unstructured":"21 CFR 3.2(e) Definitions: Combination product."},{"key":"10.1016\/j.addr.2026.115958_bb0175","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.xphs.2020.10.036","article-title":"In-use interfacial stability of monoclonal antibody formulations diluted in saline i.v. bags","volume":"110","author":"Kannan","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0180","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5731\/pdajpst.2023.012860","article-title":"Impact of NaCl on monoclonal antibody aggregation induced by agitation","volume":"78","author":"Hong","year":"2024","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103846","article-title":"Protein adsorption of in-line intravenous infusion filter and the corresponding mitigation plans","volume":"114","author":"Mu","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0190","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/19420862.2015.1087636","article-title":"Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: Implication of isoelectric precipitation of complement proteins","volume":"7","author":"Luo","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115958_bb0195","series-title":"National drug shortages: January 2001 to September 2025","author":"U.o.U.D.I. Service","year":"2025"},{"key":"10.1016\/j.addr.2026.115958_bb0200","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/jps.23008","article-title":"Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions","volume":"101","author":"Bhambhani","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0205","series-title":"All about Pre-filled Syringe Systems: From Initial Development to Final Fill Finish","author":"TRAINING","year":"2025"},{"key":"10.1016\/j.addr.2026.115958_bb0210","series-title":"Market research report, Report ID","volume":"45833","author":"M. US","year":"2023"},{"key":"10.1016\/j.addr.2026.115958_bb0215","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1016\/j.xphs.2021.07.007","article-title":"Influence of protein adsorption on aggregation in prefilled syringes","volume":"110","author":"Yoneda","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0220","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5731\/pdajpst.2012.00856","article-title":"Syringe siliconization process investigation and optimization","volume":"66","author":"Chan","year":"2012","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0225","doi-asserted-by":"crossref","first-page":"494","DOI":"10.5731\/pdajpst.2014.00991","article-title":"Characterization of the initial level and migration of silicone oil lubricant in empty prefilled syringes for biologics using infrared spectroscopy","volume":"68","author":"Bee","year":"2014","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0230","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/jps.23408","article-title":"Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces","volume":"102","author":"Gerhardt","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0235","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.xphs.2016.02.019","article-title":"Silicone oil microdroplets can induce antibody responses against recombinant murine growth hormone in mice","volume":"105","author":"Chisholm","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0240","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s11095-012-0696-6","article-title":"Mechanistic understanding of protein-silicone oil interactions","volume":"29","author":"Li","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115958_bb0245","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1039\/c2sm26184g","article-title":"Production of particles of therapeutic proteins at the air\u2013water interface during compression\/dilation cycles","volume":"8","author":"Bee","year":"2012","journal-title":"Soft Matter"},{"key":"10.1016\/j.addr.2026.115958_bb0250","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1002\/jps.23328","article-title":"Silicone-oil-based subvisible particles: their detection, interactions, and regulation in prefilled container closure systems for biopharmaceuticals","volume":"101","author":"Felsovalyi","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0255","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1039\/c2sm07017k","article-title":"Importance of the dynamics of adsorption and of a transient interfacial stress on the formation of aggregates of IgG antibodies","volume":"8","author":"Rudiuk","year":"2012","journal-title":"Soft Matter"},{"key":"10.1016\/j.addr.2026.115958_bb0260","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1208\/s12249-011-9617-y","article-title":"Development of biotechnology products in pre-filled syringes: technical considerations and approaches","volume":"12","author":"Badkar","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115958_bb0265","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1002\/jps.22515","article-title":"Evaluation of the effect of syringe surfaces on protein formulations","volume":"100","author":"Majumdar","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0270","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/jps.23973","article-title":"Protein aggregation and particle formation in prefilled glass syringes","volume":"103","author":"Gerhardt","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0275","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/jps.21719","article-title":"Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution","volume":"98","author":"Thirumangalathu","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0280","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/jps.21530","article-title":"Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality","volume":"98","author":"Carpenter","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0285","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1016\/j.xphs.2020.07.033","article-title":"Impact of surfactants on the functionality of prefilled syringes","volume":"109","author":"Wang","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0290","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jps.23434","article-title":"IgG1 aggregation and particle formation induced by silicone-water interfaces on siliconized borosilicate glass beads: a model for siliconized primary containers","volume":"102","author":"Basu","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0295","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1167\/iovs.65.13.56","article-title":"Exposure to silicone oil endotamponades induces VEGF antibody aggregation and loss of functionality","volume":"65","author":"Wohlfart","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0300","doi-asserted-by":"crossref","first-page":"1993768","DOI":"10.1080\/19420862.2021.1993768","article-title":"Impact of IgG subclass on molecular properties of monoclonal antibodies","volume":"13","author":"Tang","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115958_bb0305","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40942-021-00338-0","article-title":"The risks behind the widespread use of siliconized syringes in the healthcare practice","volume":"7","author":"Melo","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.addr.2026.115958_bb0310","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.xphs.2023.05.017","article-title":"Variables impacting silicone oil migration and biologics in prefilled syringes","volume":"112","author":"Gentile","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0315","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejpb.2015.08.009","article-title":"Analysis of thin baked-on silicone layers by FTIR and 3D-Laser Scanning Microscopy","volume":"96","author":"Funke","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115958_bb0320","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejpb.2023.07.015","article-title":"Evaluation of a novel silicone oil free primary packaging system with PTFE-based barrier stopper for biologics","volume":"190","author":"Moll","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115958_bb0325","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s11095-011-0621-4","article-title":"Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity","volume":"29","author":"Seidl","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115958_bb0330","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/jps.21707","article-title":"Precipitation of a monoclonal antibody by soluble tungsten","volume":"98","author":"Bee","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11095-018-2496-0","article-title":"Fragmentation of a monoclonal antibody by peroxotungstate","volume":"35","author":"Rathnayaka","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115958_bb0340","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1002\/jps.21778","article-title":"Tungsten-induced protein aggregation: solution behavior","volume":"98","author":"Jiang","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0345","first-page":"11","article-title":"Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes","volume":"64","author":"Liu","year":"2010","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0350","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1021\/acs.molpharmaceut.5c01652","article-title":"Mechanistic Investigation of Zn(II) Extraction and Interactions in Combination Biological Drug Products","volume":"23","author":"Song","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115958_bb0355","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/jps.20347","article-title":"Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution","volume":"94","author":"Liu","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0360","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1016\/j.xphs.2020.09.014","article-title":"Comparison of strategies in development and manufacturing of low viscosity, ultra-high concentration formulation for IgG1 antibody","volume":"109","author":"Deokar","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0365","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.xphs.2017.06.017","article-title":"A formulation development approach to identify and select stable ultra-high-concentration monoclonal antibody formulations with reduced viscosities","volume":"106","author":"Whitaker","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0370","doi-asserted-by":"crossref","first-page":"2550757","DOI":"10.1080\/19420862.2025.2550757","article-title":"Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics","volume":"17","author":"Cruz","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.addr.2026.115958_bb0375","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/19420862.2015.1128606","article-title":"Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development","volume":"8","author":"Tomar","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115958_bb0380","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejpb.2014.01.009","article-title":"Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions","volume":"87","author":"Allmendinger","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115958_bb0385","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejpb.2022.05.009","article-title":"Needle clogging of protein solutions in prefilled syringes: A two-stage process with various determinants","volume":"176","author":"Scheler","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115958_bb0390","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jpba.2017.05.008","article-title":"Non-volatile extractable analysis of prefilled syringes for parenteral administration of drug products","volume":"142","author":"Dorival-Garc\u00eda","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2026.115958_bb0395","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s11095-021-03096-8","article-title":"Predicting leachables solubilization in polysorbate 80 solutions by a linear solvation energy relationship (LSER)","volume":"38","author":"Strobel","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115958_bb0400","first-page":"423","article-title":"Recognition and identification of UV-absorbing leachables in EPREX pre-filled syringes: an unexpected occurrence at a formulation-component interface","volume":"61","author":"Pang","year":"2007","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0405","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/ICB.0000000000000570","article-title":"Large silicone droplets after intravitreal bevacizumab (avastin)","volume":"13","author":"Avery","year":"2019","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.addr.2026.115958_bb0410","author":"A.P. Ltd"},{"key":"10.1016\/j.addr.2026.115958_bb0415","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1208\/s12249-021-02086-8","article-title":"Recommended best practices for lyophilization validation-2021 part i: process design and modeling","volume":"22","author":"Jameel","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115958_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120314","article-title":"Prefilled dual chamber devices (DCDs) - Promising high-quality and convenient drug delivery system","volume":"597","author":"Ingle","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115958_bb0425","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1208\/s12249-020-01912-9","article-title":"Evaluation of microwave vacuum drying as an alternative to freeze-drying of biologics and vaccines: the power of simple modeling to identify a mechanism for faster drying times achieved with microwave","volume":"22","author":"Bhambhani","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115958_bb0430","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5731\/pdajpst.2016.006601","article-title":"A method to determine the kinetics of solute mixing in liquid\/liquid formulation dual-chamber syringes","volume":"71","author":"Werk","year":"2017","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17218209","article-title":"Brief report on double-chamber syringes patents and implications for infusion therapy safety and efficiency","volume":"17","author":"Sousa","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.addr.2026.115958_bb0440","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.xphs.2023.01.029","article-title":"Patient-centric product development: a summary of select regulatory CMC and Device considerations","volume":"112","author":"Algorri","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0445","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bmjinnov-2016-000157","article-title":"Defining patient centricity with patients for patients and caregivers: a collaborative endeavour","volume":"3","author":"Yeoman","year":"2017","journal-title":"BMJ Innov"},{"key":"10.1016\/j.addr.2026.115958_bb0450","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/08998280.2006.11928181","article-title":"Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus","volume":"19","author":"Bond","year":"2006","journal-title":"Proc. (Baylor Univ. Med. Cent.)"},{"key":"10.1016\/j.addr.2026.115958_bb0455","series-title":"Byetta (exenatide) approval letter","author":"U.S. Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.addr.2026.115958_bb0460","series-title":"Bydureon (exenatide extended-release for injectable suspension) approval package","author":"U.S. Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.addr.2026.115958_bb0465","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","article-title":"Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes","volume":"13","author":"DeYoung","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb0470","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/dom.13056","article-title":"Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes","volume":"20","author":"Wysham","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2026.115958_bb0475","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/dom.12908","article-title":"Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study","volume":"19","author":"Gadde","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2026.115958_bb0480","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/1932296818798376","article-title":"Evaluation of the use of exenatide once-weekly suspension autoinjector among patients with type 2 diabetes mellitus and health care professionals","volume":"13","author":"LaRue","year":"2019","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0485","series-title":"Bydureon BCise approval package","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.addr.2026.115958_bb0490","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0169-409X(97)00050-1","article-title":"One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate","volume":"28","author":"Okada","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115958_bb0495","first-page":"520","article-title":"Long-acting injectable PLGA\/PLA depots for leuprolide acetate: successful translation from bench to clinic, Drug Deliv","volume":"13","author":"Abulateefeh","year":"2023","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2026.115958_bb0500","series-title":"LUPRON DEPOT prescribing information","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.addr.2026.115958_bb0505","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/19322968221145201","article-title":"Factors affecting performance of insulin pen injector technology: a narrative review","volume":"17","author":"Sparre","year":"2023","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0510","doi-asserted-by":"crossref","DOI":"10.1177\/19322968251395041","article-title":"Key attributes of a reusable insulin pen injector that balances optimal insulin delivery with sustainability","author":"Wernersson","year":"2025","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0515","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2337\/ds17-0048","article-title":"Comparison of usability, accuracy, preference, and satisfaction among three once-weekly GLP-1 receptor agonist pen devices","volume":"31","author":"Zhou","year":"2018","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.addr.2026.115958_bb0520","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.xphs.2023.12.022","article-title":"A review of recent FDA-approved biologic-device combination products","volume":"113","author":"Guo","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0525","doi-asserted-by":"crossref","DOI":"10.2337\/db20-236-OR","article-title":"236-OR: molecular and biological properties of insulin icodec, a new insulin analog designed to give a long half-life suitable for once-weekly dosing","volume":"69","author":"Nishimura","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2026.115958_bb0530","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2022474","article-title":"Once-weekly insulin for Type 2 diabetes without previous insulin treatment","volume":"383","author":"Rosenstock","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0535","series-title":"Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials","author":"E.L.A. Company","year":"2025"},{"key":"10.1016\/j.addr.2026.115958_bb0540","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1586\/17434440.4.2.109","article-title":"HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab","volume":"4","author":"Kivitz","year":"2007","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.addr.2026.115958_bb0545","article-title":"The reliability of auto-injectors in clinical use: A systematic review","volume":"15","author":"Dostal","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.addr.2026.115958_bb0550","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13346-025-01883-z","article-title":"A phase I clinical study to evaluate rapid, high-volume, subcutaneous auto-injector tolerability with recombinant human hyaluronidase","volume":"16","author":"Kang","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.addr.2026.115958_bb0555","doi-asserted-by":"crossref","first-page":"2402713","DOI":"10.1080\/19420862.2024.2402713","article-title":"Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products","volume":"16","author":"Green","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115958_bb0560","doi-asserted-by":"crossref","first-page":"1331058","DOI":"10.3389\/fmedt.2024.1331058","article-title":"Risks and benefits associated with the primary functions of artificial intelligence powered autoinjectors","volume":"6","author":"Machal","year":"2024","journal-title":"Front. Med. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0565","first-page":"1238","article-title":"Pressure and stress transients in autoinjector devices, Drug Deliv","volume":"8","author":"Veilleux","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2026.115958_bb0570","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/jps.23945","article-title":"Functional evaluation and characterization of a newly developed silicone oil-free prefillable syringe system","volume":"103","author":"Yoshino","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3897\/pharmacia.72.e154045","article-title":"Long-acting injectable biologics: a game-changer in immunopharmacology","volume":"72","author":"Jawad","year":"2025","journal-title":"Pharmacia"},{"key":"10.1016\/j.addr.2026.115958_bb0580","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.xphs.2016.04.009","article-title":"Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery","volume":"105","author":"Doughty","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbiomech.2022.110995","article-title":"The biomechanics of autoinjector-skin interactions during dynamic needle insertion","volume":"134","author":"Sree","year":"2022","journal-title":"J. Biomech."},{"key":"10.1016\/j.addr.2026.115958_bb0590","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1177\/19322968241231996","article-title":"The needle shield size and applied force of subcutaneous autoinjectors significantly influence the injection depth","volume":"19","author":"Staples","year":"2025","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0595","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/PPA.S127508","article-title":"Poveda Andr\u00e9s, Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(\u00ae) in patients with multiple sclerosis","volume":"11","author":"Edo Solsona","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.addr.2026.115958_bb0600","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2147\/PPA.S154181","article-title":"Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study","volume":"12","author":"Vermeire","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.addr.2026.115958_bb0605","series-title":"Applying Human Factors and Usability Engineering to Medical Devices Guidance for Industry and Food and Drug Administration Staff","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.addr.2026.115958_bb0610","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjmed.2013.09.009","article-title":"Anaphylaxis treatment: ergonomics of epinephrine autoinjector design","volume":"127","author":"Dennerlein","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0615","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/PPA.S160394","article-title":"Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system","volume":"12","author":"Xiao","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.addr.2026.115958_bb0620","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/2327857923121042","article-title":"Autoinjector design parameters: a human factors perspective","volume":"12","author":"Elkefi","year":"2023","journal-title":"Proceedings of the International Symposium on Human Factors and Ergonomics in Health Care"},{"key":"10.1016\/j.addr.2026.115958_bb0625","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2345\/0899-8205-54.3.178","article-title":"Analysis: using the FDA MAUDE and medical device recall databases to design better devices","volume":"54","author":"Liebel","year":"2020","journal-title":"Biomed. Instrum. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0630","doi-asserted-by":"crossref","first-page":"468","DOI":"10.5731\/pdajpst.2011.00785","article-title":"Variability in syringe components and its impact on functionality of delivery systems","volume":"65","author":"Rathore","year":"2011","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0635","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41120-018-0027-z","article-title":"Improving the safety of disposable auto-injection devices: a systematic review of use errors","volume":"4","author":"Weinhold","year":"2018","journal-title":"AAPS Open"},{"key":"10.1016\/j.addr.2026.115958_bb0640","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.xphs.2022.01.028","article-title":"Risk mitigation of plunger-stopper displacement under low atmospheric pressure by establishing design space for filling-stoppering process of prefilled syringes: a design of experiment (DoE) approach","volume":"111","author":"Mehta","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0645","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1021\/acs.molpharmaceut.5c01525","article-title":"Elucidating the mechanism of protein particle formation under mechanical stress at different compressible interfaces by molecular dynamics and experiments","volume":"23","author":"Sarter","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115958_bb0650","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.xphs.2020.06.014","article-title":"Using first principles to link silicone oil\/formulation interfacial tension with syringe functionality in pre-filled syringes systems","volume":"109","author":"Richard","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122210","article-title":"The air entrainment and hydrodynamic shear of the liquid slosh in syringes","volume":"627","author":"Eshraghi","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115958_bb0660","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/01932690701345893","article-title":"Effect of surfactant concentration and operating temperature on the drop size distribution of silicon oil water dispersion","volume":"28","author":"El-Hamouz","year":"2007","journal-title":"J. Dispers. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0665","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jcis.2021.08.211","article-title":"Dewetting of non-polar thin lubricating films underneath polar liquid drops on slippery surfaces","volume":"607","author":"Bhatt","year":"2022","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2026.115958_bb0670","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1080\/03007995.2020.1783219","article-title":"Performance characterization of spring actuated autoinjector devices for Emgality and Aimovig","volume":"36","author":"Dou","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.addr.2026.115958_bb0675","series-title":"Breaking point: Assessing and Addressing the Risk of Auto-Injector Failure","author":"Barichello","year":"2024"},{"key":"10.1016\/j.addr.2026.115958_bb0680","series-title":"Plastic Prefilled Syringes: A Better Fit for Autoinjector Systems","author":"Douglas Stout","year":"2009"},{"key":"10.1016\/j.addr.2026.115958_bb0685","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1111\/dom.16455","article-title":"The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real-world retrospective cohort study","volume":"27","author":"Haughton","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2026.115958_bb0690","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2337\/dc06-0986","article-title":"OmniPod insulin management system: patient perceptions, preference, and glycemic control","volume":"29","author":"Zisser","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2026.115958_bb0695","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1932296818795150","article-title":"Patch pumps: are they all the same?","volume":"13","author":"Heinemann","year":"2019","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0700","first-page":"944","article-title":"Advancements in insulin pumps: A comprehensive exploration of insulin pump systems","author":"Rimon","year":"2024","journal-title":"Technol. Future Directions, Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115958_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071406","article-title":"A comprehensive review of the evolution of insulin development and its delivery method","volume":"14","author":"Sugumar","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115958_bb0710","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1089\/dia.2025.0129","article-title":"Research gaps, challenges, and opportunities in automated insulin delivery systems","volume":"27","author":"Jacobs","year":"2025","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb0715","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMoa2205225","article-title":"Multicenter, randomized trial of a bionic pancreas in type 1 diabetes","volume":"387","author":"Russell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0720","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1056\/NEJMoa1314474","article-title":"Outpatient glycemic control with a bionic pancreas in type 1 diabetes","volume":"371","author":"Russell","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0725","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1089\/dia.2016.0043","article-title":"A Simplified semiquantitative meal bolus strategy combined with single- and dual-hormone closed-loop delivery in patients with type 1 diabetes: a pilot study","volume":"18","author":"Gingras","year":"2016","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb0730","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2337\/dc22-1692","article-title":"Simplified meal announcement versus precise carbohydrate counting in adolescents With Type 1 diabetes using the minimed 780G advanced hybrid closed loop system: A randomized controlled trial comparing glucose control","volume":"46","author":"Petrovski","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2026.115958_bb0735","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4155\/tde-2020-0055","article-title":"Review of the omnipod(\u00ae) 5 automated glucose control system powered by horizon\u2122 for the treatment of type 1 diabetes","volume":"11","author":"Cobry","year":"2020","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2026.115958_bb0740","series-title":"Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes","author":"Corporation","year":"2026"},{"key":"10.1016\/j.addr.2026.115958_bb0745","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/dia.2015.0342","article-title":"Reduced silent occlusions with a novel catheter infusion set (BD FlowSmart): Results from two open-label comparative studies","volume":"18","author":"Gibney","year":"2015","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb0750","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1089\/dia.2010.0224","article-title":"Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial","volume":"13","author":"van Bon","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb0755","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1177\/1932296815604438","article-title":"Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high Risk for adverse events:results from a prospective randomized crossover study","volume":"9","author":"Pf\u00fctzner","year":"2015","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0760","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1932296817700545","article-title":"Insulin pump occlusions: For patients who have been around the (Infusion) block","volume":"11","author":"Klonoff","year":"2017","journal-title":"J. DiabetesSci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0765","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1056-8727(01)00168-4","article-title":"A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump","volume":"15","author":"Raskin","year":"2001","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.addr.2026.115958_bb0770","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1109\/OJEMB.2024.3408092","article-title":"Performance of a continuous subcutaneous insulin infusion (CSII) pump with acoustic volume and flow sensing in simulated high-consequence situations","volume":"5","author":"Butterfield","year":"2024","journal-title":"IEEE Open J Eng Med Biol"},{"key":"10.1016\/j.addr.2026.115958_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101325","article-title":"Structural principles of insulin formulation and analog design: A century of innovation","volume":"52","author":"Jarosinski","year":"2021","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.addr.2026.115958_bb0780","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1177\/19322968211022321","article-title":"Diabetes technology and waste: A complex story","volume":"16","author":"Heinemann","year":"2022","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0785","article-title":"Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way","author":"Whooley","year":"2025","journal-title":"Drug Delivery Business News"},{"key":"10.1016\/j.addr.2026.115958_bb0790","unstructured":"A. Medical, AMF medical receives FDA breakthrough device designation for Its Sigi\u2122 insulin management system, PR Newswire (Nov 30,2021)."},{"key":"10.1016\/j.addr.2026.115958_bb0795","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/193229680800200423","article-title":"The implantable peritoneal pump--a patient's perspective","volume":"2","author":"Witkowski","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb0800","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.18553\/jmcp.2021.21010","article-title":"Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis","volume":"27","author":"McBride","year":"2021","journal-title":"J.f Managed Care & Specialty Pharmacy"},{"key":"10.1016\/j.addr.2026.115958_bb0805","series-title":"With filler issue resolved","author":"Stanton","year":"2023"},{"key":"10.1016\/j.addr.2026.115958_bb0810","series-title":"FDA Approves Autoinjector Version of Neulasta Biosimilar","author":"Jeremias","year":"2023"},{"key":"10.1016\/j.addr.2026.115958_bb0815","series-title":"Comparing grade 4 neutropenia associated with pegfilgrastim administered via the Onpro device versus manual injection with a prefilled syringe","author":"Townley","year":"2018"},{"key":"10.1016\/j.addr.2026.115958_bb0820","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.14309\/01.ajg.0000897660.07812.b5","article-title":"S38 on-body injector administration of risankizumab for treatment of moderate-to-severe crohn\u2019s disease: Data from the fortify open-label longitudinal real-life handling substudy","volume":"117","author":"Loftus","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2026.115958_bb0825","unstructured":"J.J. Polania Gutierrez, S. Munakomi, Intramuscular injection, statpearls, StatPearls Publishing Copyright \u00a9, FL, p. 2025."},{"key":"10.1016\/j.addr.2026.115958_bb0835","first-page":"769","article-title":"Palivizumab for the prevention of respiratory syncytial virus infection","volume":"56","author":"Rogovik","year":"2010","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.addr.2026.115958_bb0840","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00003495-199958020-00009","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2026.115958_bb0845","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2024-069510","article-title":"Effectiveness of nirsevimab against RSV and RSV-related events in infants","volume":"156","author":"Hsiao","year":"2025","journal-title":"Pediatrics"},{"key":"10.1016\/j.addr.2026.115958_bb0850","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0855","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for prevention of RSV disease in healthy infants","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0860","first-page":"588","article-title":"Pulmonary drug delivery","volume":"56","author":"Labiris","year":"2003","journal-title":"Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications, Br J Clin Pharmacol"},{"key":"10.1016\/j.addr.2026.115958_bb0865","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/rr58","article-title":"The lung as a route for systemic delivery of therapeutic proteins and peptides","volume":"2","author":"Agu","year":"2001","journal-title":"Respir. Res."},{"key":"10.1016\/j.addr.2026.115958_bb0870","first-page":"131","article-title":"Inhalation drug delivery devices: technology update","volume":"8","author":"Ibrahim","year":"2015","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.addr.2026.115958_bb0875","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/03639040802144211","article-title":"Current therapies and technological advances in aqueous aerosol drug delivery","volume":"34","author":"Watts","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2026.115958_bb0880","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1081-1206(10)62933-X","article-title":"Metered dose inhaler: past, present, and future","volume":"80","author":"Vaswani","year":"1998","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.addr.2026.115958_bb0885","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.rmed.2012.12.007","article-title":"Inhaler devices - from theory to practice","volume":"107","author":"Sanchis","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0890","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2018.07.035","article-title":"Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942","volume":"35","author":"Burgess","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2026.115958_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2022.102184","article-title":"Development of an inhaled anti-TSLP therapy for asthma","volume":"78","author":"O'Byrne","year":"2023","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb0900","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-3099(23)00393-6","article-title":"Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1\/2 trial","volume":"24","author":"Maranda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2026.115958_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105582","article-title":"A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers","volume":"113","author":"Moench","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.addr.2026.115958_bb0910","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/ibd.21252","article-title":"Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease","volume":"16","author":"van der Woude","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.addr.2026.115958_bb0915","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.709861","article-title":"Nasal administration of anti-CD3 Monoclonal antibody (Foralumab) reduces lung inflammation and blood inflammatory biomarkers in mild to moderate COVID-19 patients: A pilot study","volume":"12","author":"Moreira","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115958_bb0920","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jconrel.2020.07.031","article-title":"Intravitreal hydrogels for sustained release of therapeutic proteins","volume":"326","author":"Ilochonwu","year":"2020","journal-title":"J. Control. Release"},{"issue":"633","key":"10.1016\/j.addr.2026.115958_bb0925","first-page":"e631","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115958_bb0930","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115958_bb0935","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.addr.2026.115958_bb0940","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s40123-024-01002-0","article-title":"Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review","volume":"13","author":"Uzzan","year":"2024","journal-title":"Ophthalmol Therapy"},{"key":"10.1016\/j.addr.2026.115958_bb0945","author":"Your Guide to the Susvimo\u00ae Implant Procedure"},{"key":"10.1016\/j.addr.2026.115958_bb0950","author":"Genentech to Re-Introduce Susvimo for Wet AMD"},{"key":"10.1016\/j.addr.2026.115958_bb0955","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.apsb.2019.01.004","article-title":"Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides\/proteins","volume":"9","author":"Han","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115958_bb0960","series-title":"NCT01759056 Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis","author":"ClinicalTrials.gov ID","year":"2026"},{"key":"10.1016\/j.addr.2026.115958_bb0965","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/ecco-jcc\/jjw036","article-title":"AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial","volume":"10","author":"Harris","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.addr.2026.115958_bb0970","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/jn\/125.5.1238","article-title":"15N-labeled immunoglobulins from bovine colostrum are partially resistant to digestion in human intestine","volume":"125","author":"Roos","year":"1995","journal-title":"J. Nutr."},{"key":"10.1016\/j.addr.2026.115958_bb0975","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ibd.21403","article-title":"Importance of disrupted intestinal barrier in inflammatory bowel diseases","volume":"17","author":"Salim","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.addr.2026.115958_bb0980","series-title":"A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis","author":"ClinicalTrials.gov ID NCT06080048","year":"2026"},{"key":"10.1016\/j.addr.2026.115958_bb0985","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ecco-jcc\/jjae190.0031","article-title":"OP31 Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF\/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis","volume":"19","author":"Jairath","year":"2025","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.addr.2026.115958_bb0990","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/jbm.a.34532","article-title":"pH-responsive hydrogels with dispersed hydrophobic nanoparticles for the oral delivery of chemotherapeutics","volume":"101","author":"Schoener","year":"2013","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.addr.2026.115958_bb0995","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1023\/A:1016054306763","article-title":"Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach","volume":"13","author":"Patel","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115958_bb1000","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0168-3659(91)90044-E","article-title":"Controlled release by using poly(methacrylic acid-g-ethylene glycol) hydrogels","volume":"16","author":"Peppas","year":"1991","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115958_bb1005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1163\/156856296X00444","article-title":"Swelling\/syneresis phenomena in gel-forming interpolymer complexes","volume":"7","author":"Bell","year":"1996","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.addr.2026.115958_bb1010","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0142-9612(00)00154-X","article-title":"Perivascular graft heparin delivery using biodegradable polymer wraps","volume":"21","author":"Edelman","year":"2000","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115958_bb1015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejps.2004.10.010","article-title":"Coating alginate microspheres with a serum albumin-alginate membrane: application to the encapsulation of a peptide","volume":"24","author":"Hurteaux","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1020","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1016\/S0142-9612(03)00408-3","article-title":"Preparation and modification of N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride nanoparticle as a protein carrier","volume":"24","author":"Xu","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115958_bb1025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2004.02.002","article-title":"A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery","volume":"96","author":"Chen","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115958_bb1030","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41591-019-0598-9","article-title":"A luminal unfolding microneedle injector for oral delivery of macromolecules","volume":"25","author":"Abramson","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115958_bb1035","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.aau2277","article-title":"An ingestible self-orienting system for oral delivery of macromolecules","volume":"363","author":"Abramson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115958_bb1040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41587-021-01024-0","article-title":"Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors","volume":"40","author":"Abramson","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115958_bb1045","series-title":"Immunization, Vaccines and Biologicals: Vaccine preventable deaths","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.addr.2026.115958_bb1050","unstructured":"Fast Facts on Global Immunization, 2025."},{"key":"10.1016\/j.addr.2026.115958_bb1055","series-title":"Global Vaccine Action Plan 2011-2020","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.addr.2026.115958_bb1060","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1503\/cmaj.092048","article-title":"Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline (summary)","volume":"182","author":"Taddio","year":"2010","journal-title":"Cmaj"},{"key":"10.1016\/j.addr.2026.115958_bb1065","author":"World Health Organization 2023 data.who.int, WHO Coronavirus (COVID-19) dashboard > More resources [Dashboard]"},{"key":"10.1016\/j.addr.2026.115958_bb1070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cden.2010.06.012","article-title":"Needle phobia: etiology, adverse consequences, and patient management","volume":"54","author":"Sokolowski","year":"2010","journal-title":"Dent. Clin. N. Am."},{"key":"10.1016\/j.addr.2026.115958_bb1075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115958_bb1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100030","article-title":"Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch\u2122 in rhesus macaques: An exploratory, pre-clinical feasibility assessment","volume":"2","author":"Meyer","year":"2019","journal-title":"Vaccine X"},{"key":"10.1016\/j.addr.2026.115958_bb1085","article-title":"Guidance for industry and FDA staff: classification of products as drugs and devices and additional product classification","volume":"2017","author":"FDA","year":"2017","journal-title":"Issues"},{"key":"10.1016\/j.addr.2026.115958_bb1090","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.imlet.2019.10.013","article-title":"Mucosal vaccines: Strategies and challenges","volume":"217","author":"Li","year":"2020","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.addr.2026.115958_bb1095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.682286","article-title":"Nano and microparticles as potential oral vaccine carriers and adjuvants against infectious diseases","volume":"12","author":"Jazayeri","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2026.115958_bb1100","doi-asserted-by":"crossref","first-page":"11745","DOI":"10.1073\/pnas.89.24.11745","article-title":"Expression of hepatitis B surface antigen in transgenic plants","volume":"89","author":"Mason","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115958_bb1105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1128\/CVI.00321-06","article-title":"Expression of the human hepatitis B virus large surface antigen gene in transgenic tomato plants","volume":"14","author":"Lou","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.addr.2026.115958_bb1110","article-title":"Expression of SARS-CoV-2 Spike protein receptor binding domain on recombinant B. subtilis on spore surface: A potential COVID-19 Oral vaccine candidate","volume":"10","author":"Sung","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2026.115958_bb1115","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4161\/hv.28166","article-title":"Recent advances in oral vaccine development: yeast-derived \u03b2-glucan particles","volume":"10","author":"De Smet","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2026.115958_bb1120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12033-019-00222-1","article-title":"Edible vaccines: promises and challenges","volume":"62","author":"Kurup","year":"2020","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.addr.2026.115958_bb1125","first-page":"201","article-title":"Oral immunization and edible vaccines: a viable option or mirage","volume":"2","author":"Tam","year":"2015","journal-title":"Biotechnology in Hong Kong"},{"key":"10.1016\/j.addr.2026.115958_bb1130","article-title":"Plant-based vaccines: antigen design, diversity, and strategies for high level production","volume":"10","author":"Monreal-Escalante","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2026.115958_bb1135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.virol.2010.08.007","article-title":"Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules","volume":"407","author":"Lei","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.addr.2026.115958_bb1140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3892\/etm.2024.12511","article-title":"Recent development of oral vaccines (Review)","volume":"27","author":"Liu","year":"2024","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.addr.2026.115958_bb1145","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115958_bb1150","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/19490976.2020.1770666","article-title":"Vaccines against gastroenteritis, current progress and challenges","volume":"11","author":"Seo","year":"2020","journal-title":"Gut Microbes"},{"key":"10.1016\/j.addr.2026.115958_bb1155","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/02786829308959606","article-title":"Lung Deposition and Clearance: What can be learned from inhalation toxicology and industrial hygiene?","volume":"18","author":"Hickey","year":"1993","journal-title":"Aerosol Sci. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb1160","series-title":"Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products","author":"FDA","year":"2024"},{"key":"10.1016\/j.addr.2026.115958_bb1165","series-title":"Afrezza\u00ae Prescribing Information","author":"FDA","year":"2014"},{"key":"10.1016\/j.addr.2026.115958_bb1170","series-title":"FluMist\u00ae prescribing information","author":"FDA","year":"2003"},{"key":"10.1016\/j.addr.2026.115958_bb1175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/08998280.2005.11928028","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc. (Baylor Univ. Med. Cent.)"},{"key":"10.1016\/j.addr.2026.115958_bb1180","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2011.10.026","article-title":"Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin","volume":"158","author":"Chen","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115958_bb1185","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1473-3099(16)00133-X","article-title":"Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial","volume":"16","author":"Beals","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2026.115958_bb1190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14745\/ccdr.v41i03a03","article-title":"Immunogenicity and feasibility of intradermal vaccination against rabies in Quebec","volume":"41","author":"Bui","year":"2015","journal-title":"Can. Commun. Dis. Rep."},{"key":"10.1016\/j.addr.2026.115958_bb1195","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.3748\/wjg.v20.i30.10383","article-title":"Hepatitis B vaccine by intradermal route in non responder patients: an update","volume":"20","author":"Filippelli","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.addr.2026.115958_bb1200","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/21645515.2017.1328332","article-title":"Immunogenicity, safety and tolerability of intradermal influenza vaccines","volume":"14","author":"Hung","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2026.115958_bb1205","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.4155\/tde.15.65","article-title":"Current opportunities and challenges in intradermal vaccination","volume":"6","author":"Chen","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2026.115958_bb1210","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1016\/j.vaccine.2015.05.012","article-title":"Recent insights into cutaneous immunization: How to vaccinate via the skin","volume":"33","author":"Engelke","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb1215","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nri1728","article-title":"Immunization without needles","volume":"5","author":"Mitragotri","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2026.115958_bb1220","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.vaccine.2019.01.039","article-title":"Needle-free delivery of influenza vaccine using the Med-Jet\u00ae H4 is efficient and elicits the same humoral and cellular responses as standard IM injection: A randomized trial","volume":"37","author":"Shapiro","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb1225","author":"National Center for Immunization and Respiratory Diseases (NCIRD)"},{"key":"10.1016\/j.addr.2026.115958_bb1230","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.addr.2012.04.005","article-title":"Microneedles for drug and vaccine delivery","volume":"64","author":"Kim","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115958_bb1235","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201600750","article-title":"Ebola vaccination using a DNA vaccine coated on PLGA-PLL\/\u03b3PGA nanoparticles administered using a microneedle patch","volume":"6","author":"Yang","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115958_bb1240","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/btm2.10098","article-title":"Hepatitis B vaccination using a dissolvable microneedle patch is immunogenic in mice and rhesus macaques","volume":"3","author":"Perez Cuevas","year":"2018","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2026.115958_bb1245","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.nano.2016.11.019","article-title":"DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles","volume":"13","author":"Ali","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2026.115958_bb1250","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10202","article-title":"Intradermal delivery of receptor-binding domain of SARS-CoV-2 spike protein with dissolvable microneedles to induce humoral and cellular responses in mice","volume":"6","author":"Kuwentrai","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2026.115958_bb1255","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","article-title":"The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial","volume":"390","author":"Rouphael","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115958_bb1260","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1016\/j.vaccine.2020.07.064","article-title":"Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity","volume":"38","author":"Frew","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb1265","article-title":"Dissolvable microneedle patches to enable increased access to vaccines against SARS-CoV-2 and future pandemic outbreaks","volume":"9","author":"O'Shea","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2026.115958_bb1270","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1016\/j.vaccine.2018.05.053","article-title":"Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch\u2122)","volume":"36","author":"Fernando","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb1275","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1016\/j.vaccine.2017.10.021","article-title":"Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects","volume":"35","author":"Griffin","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115958_bb1280","article-title":"Safety, tolerability, and immunogenicity of measles and rubella vaccine delivered with a high-density microarray patch: results from a randomized, partially double-blinded, placebo-controlled phase i clinical trial","volume":"11","author":"Baker","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2026.115958_bb1285","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/pedi.12031","article-title":"Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes","volume":"14","author":"Norman","year":"2013","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.addr.2026.115958_bb1290","series-title":"Vivek Kumar Garripelli, Lyophilized lipid nanoparticles and methods of their use","author":"Isaias Prado","year":"2025"},{"key":"10.1016\/j.addr.2026.115958_bb1295","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case","volume":"112","author":"Oude Blenke","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1300","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112357","article-title":"Stability study of mRNA-lipid nanoparticles exposed to various conditions based on the evaluation between physicochemical properties and their relation with protein expression ability","volume":"14","author":"Kamiya","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115958_bb1305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114265","article-title":"Don't shake it! Mechanical stress testing of mRNA-lipid nanoparticles","volume":"198","author":"Ruppl","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115958_bb1310","author":"COMIRNATY\u00aePackage Insert"},{"key":"10.1016\/j.addr.2026.115958_bb1315","author":"Onpattro\u2122 Package Insert"},{"key":"10.1016\/j.addr.2026.115958_bb1320","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1038\/s44319-024-00216-4","article-title":"Mucosal IFN\u03bb1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice","volume":"25","author":"Macht","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.addr.2026.115958_bb1325","article-title":"Microfluidic platform enables shear-less aerosolization of lipid nanoparticles for messenger RNA inhalation","author":"Kim","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2026.115958_bb1330","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1208\/s12249-025-03133-4","article-title":"Mitigating shear stress in spray drying for RNA-loaded lipid nanoparticles through process and formulation optimization","volume":"26","author":"Farinha","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115958_bb1335","series-title":"Gene, Cell, & RNA Therapy Landscape Report","author":"ASGCT","year":"2025"},{"key":"10.1016\/j.addr.2026.115958_bb1340","author":"FDA"},{"key":"10.1016\/j.addr.2026.115958_bb1345","author":"ZEVASKYN\u2122 Package Insert"},{"key":"10.1016\/j.addr.2026.115958_bb1350","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.mayocp.2013.10.020","article-title":"Emerging medical devices for minimally invasive cell therapy","volume":"89","author":"O'Cearbhaill","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2026.115958_bb1355","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2026.115958_bb1360","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1089\/ten.tea.2011.0391","article-title":"Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers","volume":"18","author":"Aguado","year":"2012","journal-title":"Tissue Eng Part A"},{"key":"10.1016\/j.addr.2026.115958_bb1365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314681","article-title":"Optimal Intravenous Administration Procedure for Efficient Delivery of Canine Adipose-Derived Mesenchymal Stem Cells","volume":"23","author":"Yasumura","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1370","series-title":"EMA guideline: Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials","author":"EMA","year":"2025"},{"key":"10.1016\/j.addr.2026.115958_bb1375","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41536-017-0028-x","article-title":"Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges","volume":"2","author":"Amer","year":"2017","journal-title":"npj Regener. Med."},{"key":"10.1016\/j.addr.2026.115958_bb1380","series-title":"Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)","author":"FDA","year":"2020"},{"key":"10.1016\/j.addr.2026.115958_bb1385","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11123124","article-title":"Frequency and pattern of worldwide ocular gene therapy clinical trials up to 2022","volume":"11","author":"Ameri","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2026.115958_bb1390","first-page":"929","article-title":"The short-needle intravitreal injection technique","volume":"9","author":"Oztas","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.addr.2026.115958_bb1395","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/IAE.0000000000000550","article-title":"ARE intravitreal injections with ultrathin 33-g needles less painful than the commonly used 30-G needles?","volume":"35","author":"van Asten","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.addr.2026.115958_bb1400","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40012-023-00373-2","article-title":"A review on tele-manipulators for remote diagnostic procedures and surgery","volume":"11","author":"Das","year":"2023","journal-title":"CSI Trans. ICT"},{"key":"10.1016\/j.addr.2026.115958_bb1405","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1109\/TBME.2020.2996013","article-title":"A magnetically navigated microcannula for subretinal injections","volume":"68","author":"Charreyron","year":"2021","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.addr.2026.115958_bb1410","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/eye.2017.158","article-title":"Technique of retinal gene therapy: delivery of viral vector into the subretinal space","volume":"31","author":"Xue","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115958_bb1415","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/IAE.0000000000002669","article-title":"Nanovitreoretinal subretinal gateway device to displace submacular hemorrhage: access to the subretinal space without vitrectomy","volume":"42","author":"Wood","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.addr.2026.115958_bb1420","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hgtb.2016.086","article-title":"Evaluation of an optimized injection system for retinal gene therapy in human patients","volume":"27","author":"Fischer","year":"2016","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.addr.2026.115958_bb1425","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb1430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017140","article-title":"Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250 micron flexible microcatheter","volume":"6","author":"Peden","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115958_bb1435","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.37765\/ajmc.2022.89270","article-title":"Microinjection via the suprachoroidal space: a review of a novel mode of administration","volume":"28","author":"Ciulla","year":"2022","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.addr.2026.115958_bb1440","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2026.115958_bb1445","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of suprachoroidal drug delivery: From benchtop to clinical investigation in ocular therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.addr.2026.115958_bb1450","series-title":"Endotoxin Testing Recommendations for Single-Use Intraocular Ophthalmic Devices","author":"FDA","year":"2015"},{"key":"10.1016\/j.addr.2026.115958_bb1455","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41433-019-0636-3","article-title":"Ophthalmic biosimilars and biologics-role of endotoxins","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115958_bb1460","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115363","article-title":"Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications","volume":"211","author":"Ye","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115958_bb1465","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00434","article-title":"Neurosurgical gene therapy for central nervous system diseases","volume":"21","author":"Patel","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.addr.2026.115958_bb1470","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40364-024-00679-6","article-title":"Advances in CAR-T therapy for central nervous system tumors","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.addr.2026.115958_bb1475","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nec.2024.09.002","article-title":"Direct Convective Delivery for Nervous System Gene Therapy","volume":"36","author":"Elder","year":"2025","journal-title":"Neurosurg. Clin. N. Am."},{"key":"10.1016\/j.addr.2026.115958_bb1480","series-title":"Backflow mitigation in stepped catheters","author":"Brady","year":"2019"},{"key":"10.1016\/j.addr.2026.115958_bb1485","series-title":"Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery","author":"Bankiewicz","year":"2006"},{"key":"10.1016\/j.addr.2026.115958_bb1490","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2021.725844","article-title":"Design and validation of a multi-point injection technology for mr-guided convection enhanced delivery in the brain","volume":"3","author":"Prezelski","year":"2021","journal-title":"Front. Med. Technol."},{"key":"10.1016\/j.addr.2026.115958_bb1495","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneumeth.2010.12.022","article-title":"Design of an in-dwelling cannula for convection-enhanced delivery","volume":"196","author":"Rosenbluth","year":"2011","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.addr.2026.115958_bb1500","doi-asserted-by":"crossref","DOI":"10.1002\/cnm.3635","article-title":"Convection-enhanced delivery with controlled catheter movement: A parametric finite element analysis","volume":"38","author":"Mehta","year":"2022","journal-title":"Int J Numer Method Biomed Eng"},{"key":"10.1016\/j.addr.2026.115958_bb1505","author":"BIONAUT"},{"key":"10.1016\/j.addr.2026.115958_bb1510","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3389\/fphar.2019.01348","article-title":"Recent Advances in the Use of Focused Ultrasound for Magnetic Resonance Image-Guided Therapeutic Nanoparticle Delivery to the Central Nervous System","volume":"10","author":"Fisher","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2026.115958_bb1515","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.106142","article-title":"587PThecaFlex DRx™: implantable intrathecal catheter and subcutaneous port system for repeated intrathecal delivery of nusinersen","volume":"53","author":"Meyer","year":"2025","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.addr.2026.115958_bb1520","article-title":"Quantitative 3D reconstruction of viral vector distribution in rodent and ovine brain following local delivery","volume":"4","author":"Poceviciute","year":"2024","journal-title":"Neuroimage Rep"},{"key":"10.1016\/j.addr.2026.115958_bb1525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106472","article-title":"Design and development of microformulations for rapid release of small molecules and oligonucleotides","volume":"188","author":"Brown","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1530","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2021.101266","article-title":"Focused ultrasound-mediated intranasal brain drug delivery technique (FUSIN)","volume":"8","author":"Ye","year":"2021","journal-title":"MethodsX"},{"key":"10.1016\/j.addr.2026.115958_bb1535","article-title":"A magnetically powered stem cell-based microrobot for minimally invasive stem cell delivery via the intranasal pathway in a mouse brain","volume":"10","author":"Jeon","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115958_bb1540","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcyt.2024.04.067","article-title":"The science and practice of current environmental risk assessment for gene therapy: a review","volume":"26","author":"Liu","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2026.115958_bb1545","first-page":"47","article-title":"Occupational exposure of animal caretakers to cyclophosphamide","volume":"35","author":"Sessink","year":"1993","journal-title":"J. Occup. Med."},{"key":"10.1016\/j.addr.2026.115958_bb1550","volume":"288","year":"2016","journal-title":"NIOSH Docket Number"},{"key":"10.1016\/j.addr.2026.115958_bb1555","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0018578719848730","article-title":"Evaluating six commercially available closed-system drug-transfer devices against NIOSH's 2015 draft vapor protocol","volume":"55","author":"Halloush","year":"2020","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.addr.2026.115958_bb1560","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1177\/1078155218787256","article-title":"Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs","volume":"25","author":"Forshay","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.addr.2026.115958_bb1565","doi-asserted-by":"crossref","unstructured":"L.T. Armistead, M. Stepanovic, M.A. Earnhart, S.F. Eckel, An assessment of seven closed system transfer devices in accordance with the 2015 NIOSH vapor containment performance protocol, J. Oncol. Pharm. Pract., (2024) 10781552241304638.","DOI":"10.1177\/10781552241304638"},{"key":"10.1016\/j.addr.2026.115958_bb1570","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1078155210361431","article-title":"Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device","volume":"17","author":"Sessink","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.addr.2026.115958_bb1575","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ajhp\/59.1.68","article-title":"Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area","volume":"59","author":"Connor","year":"2002","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.addr.2026.115958_bb1580","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/ajhp\/zxac336","article-title":"Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system","volume":"80","author":"Brechtelsbauer","year":"2023","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.addr.2026.115958_bb1585","first-page":"148","article-title":"Safe cytotoxic drug preparation using closed-system transfer device: technical and practical evaluation of a new device (vialshield\/texium) comparatively to a reference one (phaseal)","volume":"20","author":"Garrigue","year":"2016","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.addr.2026.115958_bb1590","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41598-021-03780-0","article-title":"Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs)","volume":"12","author":"Sumikawa","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115958_bb1595","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.xphs.2019.10.042","article-title":"Challenges of using closed system transfer devices with biological drug products: an industry perspective","volume":"109","author":"Sreedhara","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1600","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.xphs.2023.11.012","article-title":"Characterization of silicone from closed system transfer devices and its migration into pharmaceutical drug products","volume":"113","author":"Wozniewski","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1605","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1208\/s12248-024-00931-9","article-title":"Impact on quality during in-use preparation of an antibody drug conjugate with eight different closed system transfer device brands","volume":"26","author":"Sorret","year":"2024","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115958_bb1610","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.xphs.2020.07.031","article-title":"Determination of holdup volume and transient contact compatibility of closed system transfer devices for a reconstituted lyophilized drug product","volume":"109","author":"Kagdi","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1615","series-title":"TR 2021\/241: An Evaluation of Elastomeric Stopper Compatibility with Closed System Transfer Devices","author":"Chapman","year":"2021"},{"key":"10.1016\/j.addr.2026.115958_bb1620","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.xphs.2020.10.047","article-title":"An industry perspective on compatibility assessment of closed system drug-transfer devices for biologics","volume":"110","author":"Besheer","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1625","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.xphs.2024.11.015","article-title":"A systematic study of CSTD-generated stress on different biomolecular modalities","volume":"114","author":"Seeler","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115958_bb1630","series-title":"Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers","author":"FDA","year":"2012"},{"key":"10.1016\/j.addr.2026.115958_bb1635","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.ymthe.2025.12.067","article-title":"Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: Underlying mechanisms and mitigating strategies","volume":"34","author":"Duan","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb1640","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ymthe.2021.01.016","article-title":"Considerations for systemic use of gene therapy","volume":"29","author":"Byrne","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115958_bb1645","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.827484","article-title":"The review of insulin pens-past, present, and look to the future","volume":"13","author":"Masierek","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.addr.2026.115958_bb1650","series-title":"Artificial Intelligence in Drug Delivery and Development","author":"Abioye","year":"2022"},{"key":"10.1016\/j.addr.2026.115958_bb1655","doi-asserted-by":"crossref","DOI":"10.2196\/39047","article-title":"Use of an ingestible, sensor-based digital adherence system to strengthen the therapeutic relationship in serious mental illness","volume":"9","author":"Richey","year":"2022","journal-title":"JMIR Ment. Health"},{"key":"10.1016\/j.addr.2026.115958_bb1660","doi-asserted-by":"crossref","DOI":"10.3390\/ph15081025","article-title":"Digital Pills with Ingestible Sensors: Patent Landscape Analysis","volume":"15","author":"Litvinova","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.addr.2026.115958_bb1665","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016982","article-title":"Economic impact of medication non-adherence by disease groups: a systematic review","volume":"8","author":"Cutler","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.addr.2026.115958_bb1670","series-title":"FDA grants breakthrough device designation for implantable insulin pump","author":"Isaacs","year":"2026"},{"key":"10.1016\/j.addr.2026.115958_bb1675","author":"P. Diabetes\u2122"},{"key":"10.1016\/j.addr.2026.115958_bb1680","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/sci7040179","article-title":"A review of artificial Intelligence (AI)-driven smart and sustainable drug delivery systems: A dual-framework roadmap for the next pharmaceutical paradigm","volume":"7","author":"Suksaeree","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115958_bb1685","unstructured":"U.S. Food and Drug Administration. Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff, 2025."},{"key":"10.1016\/j.addr.2026.115958_bb1690","series-title":"Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry and Other Interested Parties","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.addr.2026.115958_bb1695","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s11671-024-04131-4","article-title":"Nanorobots mediated drug delivery for brain cancer active targeting and controllable therapeutics","volume":"19","author":"Xu","year":"2024","journal-title":"Discov Nano"},{"key":"10.1016\/j.addr.2026.115958_bb1700","doi-asserted-by":"crossref","first-page":"14196","DOI":"10.1021\/acsnano.3c03723","article-title":"Microrobots for biomedicine: unsolved challenges and opportunities for translation","volume":"17","author":"Lee","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115958_bb1705","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2019.111334","article-title":"Biocompatible propulsion for biomedical micro\/nano robotics","volume":"139","author":"Halder","year":"2019","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.addr.2026.115958_bb1710","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1039\/D3NR03516F","article-title":"Steerable acoustically powered starfish-inspired microrobot","volume":"16","author":"Dillinger","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115958_bb1715","doi-asserted-by":"crossref","DOI":"10.3390\/molecules31010086","article-title":"Magnetic microrobots for drug delivery: a review of fabrication materials, structure designs and drug delivery strategies","volume":"31","author":"Shi","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115958_bb1720","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s44172-023-00145-5","article-title":"Programming structural and magnetic anisotropy for tailored interaction and control of soft microrobots","volume":"3","author":"Yan","year":"2024","journal-title":"Commun. Eng."},{"key":"10.1016\/j.addr.2026.115958_bb1725","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s44182-025-00058-9","article-title":"Artificial spacetimes for reactive control of resource-limited robots","volume":"3","author":"Reinhardt","year":"2025","journal-title":"npj Robotics"},{"key":"10.1016\/j.addr.2026.115958_bb1730","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4155\/tde-2017-0113","article-title":"Micro- and nano-motors: the new generation of drug carriers","volume":"9","author":"Medina-S\u00e1nchez","year":"2018","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2026.115958_bb1735","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0002-9343(70)80078-X","article-title":"Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis","volume":"49","author":"Falchuk","year":"1970","journal-title":"Am. J. Med."},{"key":"10.1016\/j.addr.2026.115958_bb1740","doi-asserted-by":"crossref","first-page":"2311462","DOI":"10.1002\/adma.202311462","article-title":"Roadmap for clinical translation of mobile microrobotics","volume":"36","author":"Bozuyuk","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115958_bb1745","doi-asserted-by":"crossref","first-page":"1416314","DOI":"10.3389\/fchem.2024.1416314","article-title":"Hydrogel microrobots for biomedical applications","volume":"12","author":"Song","year":"2024","journal-title":"Front Chem"},{"key":"10.1016\/j.addr.2026.115958_bb1750","doi-asserted-by":"crossref","first-page":"28","DOI":"10.55544\/jrasb.3.4.5","article-title":"Advancements in Soft Robotic Implants for Long-Term Drug Delivery and Tissue Monitoring","volume":"3","author":"Yadav","year":"2024","journal-title":"J. Res. Appl. Sci. Biotechnol."},{"key":"10.1016\/j.addr.2026.115958_bb1755","article-title":"Nano bio-robots: a new frontier in targeted therapeutic delivery","volume":"12","author":"Anto","year":"2025","journal-title":"Front. Rob. AI"},{"key":"10.1016\/j.addr.2026.115958_bb1760","article-title":"Design, control, and clinical applications of magnetic actuation systems: challenges and opportunities","volume":"7","author":"Huo","year":"2025","journal-title":"Adv. Intelligent Syst."},{"key":"10.1016\/j.addr.2026.115958_bb1765","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11517-010-0636-8","article-title":"Dynamics of magnetic particles in cylindrical Halbach array: implications for magnetic cell separation and drug targeting","volume":"48","author":"Babinec","year":"2010","journal-title":"Med. Biol. Eng. Comput."},{"key":"10.1016\/j.addr.2026.115958_bb1770","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1126\/science.adx1708","article-title":"Clinically ready magnetic microrobots for targeted therapies","volume":"390","author":"Landers","year":"2025","journal-title":"Science"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T13:14:24Z","timestamp":1788700464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":353,"alternative-id":["S0169409X26001924"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115958","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From conventional biologics\u2013device combination products to advanced therapies: current state and future trends in patient-centric delivery","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115958"}}